Streetbeat News

Products Services

MASI

Masimo (NASDAQ:MASI) announced results from a peer-reviewed study showing its SET Pulse Oximetry accurately measures oxygen saturation across different skin tones, even under low perfusion. The study, published in the Journal of Clinical Monitoring and Computing, analyzed over 7,000 data samples from 75 subjects, finding no significant difference in accuracy or bias between Black and White subjects. This adds to evidence supporting the reliability of Masimo SET Pulse Oximetry in diverse conditions.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:51 pm

SONY

Helldivers 2, developed by Sony Group Corp.'s Arrowhead Game Studios, launched on Feb. 8, 2024, simultaneously on PC and PS5, marking a first for PlayStation Studios. The game quickly topped Steam's Top Sellers chart, outperforming titles like Call of Duty and Palworld. This release strategy represents a significant shift for Sony, moving away from traditional console exclusivity to embrace cross-platform availability. Helldivers 2 features co-op gameplay, strategic upgrades, and full cross-platform play between PC and PS5 users.

Portfolio Pulse from Franca Quarneti

February 08, 2024 | 9:41 pm

CZR

DKNG

PARA

A bettor at Caesars Sportsbook (NASDAQ:CZR) placed a $100 bet on the Kansas City Chiefs scoring exactly two points in Super Bowl LVIII, with odds of 10,000 to 1, potentially winning $1 million. This unique bet is considered highly unlikely given the Chiefs' scoring history and the rarity of safeties in Super Bowl history. DraftKings Inc (NASDAQ:DKNG) has the 49ers favored by two points with an over/under of 47.5 points. Super Bowl LVIII will be broadcasted by CBS and Nickelodeon, and streamed on Paramount+, all owned by Paramount Global Inc (NASDAQ:PARA)(NASDAQ:PARAA).

Portfolio Pulse from Chris Katje

February 08, 2024 | 9:34 pm

DOMO

Falvey Insurance Group has selected Domo (NASDAQ:DOMO) to integrate its disparate data sources into a single platform, enabling real-time data access and actionable insights for better business decisions. This integration has led to a 5x revenue growth for Falvey, showcasing the effectiveness of Domo's platform in enhancing business operations and decision-making processes.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:29 pm

SPIR

Spire Global, Inc. (NYSE:SPIR) and Signal Ocean have announced a collaboration to digitize the maritime economy. Signal Ocean will invest $10M in Spire Global through a private placement of 833,333 shares at $12.00 per share. This partnership aims to leverage Spire's space-based data and Signal Ocean's AI expertise to enhance maritime domain monitoring, global security, and transparency.

Portfolio Pulse from Charles Gross

February 08, 2024 | 9:20 pm

PETS

PetMed Express, Inc. (NASDAQ:PETS) announced preliminary Q3 financial results, reporting a revenue of $65.3M, an 11% increase YOY, but below the $68M estimate. Gross profit rose to $17.9M with a margin of 27.4%. The company highlighted growth in recurring revenue, driven by AutoShip & Save and PetPlus programs, now representing 52.2% of revenue. Despite needing to restate previous financial statements due to tax accounting, the restatement won't affect current cash balances. PetMeds is expanding its product portfolio and enhancing its AutoShip program.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:14 pm

AMRX

Amneal has resubmitted its New Drug Application (NDA) for IPX203 to the FDA, following a Complete Response Letter. The resubmission includes data from a recent healthy volunteer study conducted in Q4 2023, with no additional studies requested by the FDA.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:13 pm

CRVS

Corvus Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to Soquelitinib for the treatment of T Cell Lymphoma. Soquelitinib, the company's lead ITK inhibitor candidate, is slated to enter a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:09 pm

RNAZ

Transcode Therapeutics has filed a U.S. patent application (#20240042070) for nanoparticles and template directed RIG-I agonist precursor compositions, aimed at cancer therapy. This development could signify a significant advancement in cancer treatment methodologies, leveraging the potential of nanoparticles in medical applications.

Portfolio Pulse from Charles Gross

February 08, 2024 | 9:03 pm

SINT

SiNtx Technologies has received an Australian patent (No. 2019336133) for 'Antipathogenic Compositions And Methods Thereof', marking a significant intellectual property milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 8:58 pm